DrugBiological
ABP 501 clinical trials
Also written ABP 501.
A product of Adalimumab; its studies count on that page too.
- studies test it
- 6
- open now
- 0
- in phase 3
- 4
- first study started
- 2013
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
6 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2014 | 2 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses ABP 501 is read from its arms, and is right about nine times in ten.
Testing it · 6
- A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult ParticipantsCompletedPhase 1AmgenNCT05909852Written as ABP 501-HCF
- A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque PsoriasisCompletedPhase 3AmgenNCT05073315Written as ABP 501
- Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese ParticipantsCompletedPhase 1AmgenNCT05995691Written as ABP 501
- Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque PsoriasisCompletedPhase 3AmgenNCT01970488Written as ABP 501
- Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid ArthritisCompletedPhase 3AmgenNCT02114931Written as ABP 501
- Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid ArthritisCompletedPhase 3AmgenNCT01970475Written as ABP 501